Osanni Bio has closed a $190 million Series B financing that the company plans to use to advance multiple pipeline programs and expand its drug discovery and development platform.

The financing was led by Patient Square Capital, with participation from existing investors the Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund.

Osanni describes itself as a development-stage therapeutics platform focused on reimagining the discovery and development of new medicines through a combination of biodesign-inspired innovation, modern technologies, and capital-efficient operating principles. Proceeds from the financing will support advancement of its existing portfolio of therapeutic candidates while helping to scale its proprietary discovery and development capabilities.

“At Osanni, we are accelerating the process of medicine discovery by leveraging biodesign-inspired innovation, modern technology and a focus on capital efficiency,” said Michael Ackermann, PhD, founder and CEO of Osanni Bio, in a company statement. “Patient Square is the perfect partner for scaling our vision, and I couldn't be more excited to build our future with them.”